GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » EV-to-FCF

Arctic Bioscience AS (OSL:ABS) EV-to-FCF : -2.26 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arctic Bioscience AS's Enterprise Value is kr193.49 Mil. Arctic Bioscience AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was kr-85.62 Mil. Therefore, Arctic Bioscience AS's EV-to-FCF for today is -2.26.

The historical rank and industry rank for Arctic Bioscience AS's EV-to-FCF or its related term are showing as below:

OSL:ABS' s EV-to-FCF Range Over the Past 10 Years
Min: -20.58   Med: -2.03   Max: -0.66
Current: -2.26

During the past 6 years, the highest EV-to-FCF of Arctic Bioscience AS was -0.66. The lowest was -20.58. And the median was -2.03.

OSL:ABS's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs OSL:ABS: -2.26

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Arctic Bioscience AS's stock price is kr10.50. Arctic Bioscience AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-1.790. Therefore, Arctic Bioscience AS's PE Ratio for today is At Loss.


Arctic Bioscience AS EV-to-FCF Historical Data

The historical data trend for Arctic Bioscience AS's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arctic Bioscience AS EV-to-FCF Chart

Arctic Bioscience AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - -2.75 -1.73 -2.26

Arctic Bioscience AS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.75 - -1.73 - -2.26

Competitive Comparison of Arctic Bioscience AS's EV-to-FCF

For the Biotechnology subindustry, Arctic Bioscience AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arctic Bioscience AS's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's EV-to-FCF falls into.



Arctic Bioscience AS EV-to-FCF Calculation

Arctic Bioscience AS's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=193.489/-85.621
=-2.26

Arctic Bioscience AS's current Enterprise Value is kr193.49 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arctic Bioscience AS's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was kr-85.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Arctic Bioscience AS  (OSL:ABS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Arctic Bioscience AS's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.50/-1.790
=At Loss

Arctic Bioscience AS's share price for today is kr10.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arctic Bioscience AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was kr-1.790.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Arctic Bioscience AS EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Arctic Bioscience AS's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Arctic Bioscience AS (OSL:ABS) Business Description

Traded in Other Exchanges
N/A
Address
Industrivegen 42, Orsta, NOR, 6155
Arctic Bioscience AS is a Norwegian biotechnology company. The company is focused on developing products and solutions based on bioactive marine compounds. The product portfolio includes nutraceuticals and pharmaceuticals. It is currently developing a novel, cost-efficient oral treatment (HRO350) for mild-to-moderate psoriasis. Its nutraceutical products are sold globally to both B2C and B2B under the Romega brand.

Arctic Bioscience AS (OSL:ABS) Headlines

No Headlines